ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2015

Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.

S Fu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.